Navigation Links
Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program
Date:12/10/2009

EMERYVILLE, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host an Analyst Briefing on December 17, 2009 at 8:30 a.m. ET.

The briefing, hosted by Onyx management, will provide an overview of its development program and feature presentations on multiple tumor types by external clinical investigators and members of management.

The live webcast, to begin at 8:30 a.m. ET, will be available on the Onyx website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

A replay of the webcast will be available on the Onyx website through December 31, 2009.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors, and ONX 0801, a targeted alpha-folate inhibitor, currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

SOURCE Onyx Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
2. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010
3. Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution
4. Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lees Pharmaceuticals
5. BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors
6. ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
7. Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis
8. Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
10. Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals Universal Flu Vaccine
11. Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , Jan 20, 2017 Research and ... Aids Market (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), ... to their offering. ... Global Hearing Aids Market Sales Volume, Company Analysis ... fast-evolving, high-growth hearing aid industry. The growing prevalence ...
(Date:1/20/2017)... 20, 2017 Stock-Callers.com today evaluates the ... SGYP ), Novo Nordisk A/S (NYSE: NVO ), ... Therapeutics Holdings Inc. (NASDAQ: PTX ). These stocks ... 19 th , 2017, finishing near its session lows. As ... over 0.7%, while shares of health care companies in the ...
(Date:1/20/2017)... BUFFALO, N.Y. , Jan. 20, 2017 /PRNewswire/ ... health programs, has announced the launch of an ... to new guidelines on opioids and helps stem ... Opioids are often prescribed to treat chronic non-cancer ... disease) despite serious risks and lack of evidence ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global business ... recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, strongly ... to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice are ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting “Coming ... friends, and community. “Coming Home 2017” will be held on Friday January ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics ... Petaluma, located at 167 Lynch Creek Way. The Petaluma office features three comfortable ... and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons ...
(Date:1/21/2017)... Texas (PRWEB) , ... January 21, 2017 , ... ... performed by Austin, Texas Periodontist Dr. Dan Holtzclaw in media for its creos™ ... features two surgeries performed by Dr. Holtzclaw in which he utilizes creos™ allo.gain™ ...
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® and Roadie, ... use or need, from clothes to couches to dressers and bicycles. Roadie — the ... to the nearest Goodwill donation center through February 28th. , “January is an ...
Breaking Medicine News(10 mins):